Acute Lymphatic Leukemia clinical trials

Explore recruiting acute lymphatic leukemia clinical trials.

Recruiting acute lymphatic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Lymphatic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare end of therapy with indication for SCT versus TKI, blinatumomab and chemotherapy in optimal responders and to evaluate blinatumomab in suboptimal responders (GMALL-EVOLVE)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children – sub protocol B

Netherlands, Spain, Norway, Sweden, Denmark, Germany +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Acute Lymphatic Leukemia trials by city

Acute Lymphatic Leukemia clinical trials

Recruiting acute lymphatic leukemia studies right now

Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Novel Approaches to Target MECOM/EVI1 in AML

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Venetoclax and Decitabine in R/R T-ALL

Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Also recruiting in Europe

A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children – sub protocol B

Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies

Acute Lymphatic Leukemia trials by city

Other conditions